2015 New Hampshire Revised Statutes
Title XXXI - TRADE AND COMMERCE
Chapter 359-O - SALE OF SYNTHETIC DRUGS
Section 359-O:2 - Definitions.

    359-O:2 Definitions. – In this chapter:
    I. "Person'' means an individual, including a clerk, manager, or owner of a business.
    II. "Business'' means a corporation, limited liability company, partnership, wholesaler, retailer, and any licensed or unlicensed business.
    III. (a) "Isomer'' shall mean and include all optical, geometric, and positional isomers of a controlled substance, synthetic cannabinoid, synthetic cathinone, or miscellaneous psychoactive substance.
       (b) A positional isomer shall mean any and all substances which:
          (1) Are not already scheduled.
          (2) Have the same molecular formula and core structure as a controlled substance, synthetic cannabinoid, substituted cathinone, or listed miscellaneous psychoactive substance.
          (3) Have the same functional group(s) and/or substituents as those found in the controlled substance, synthetic cannabinoid, substituted cathinone, or miscellaneous psychoactive substance, attached at any positions on the core structure, but in such manner that no new chemical functionalities are created and no existing chemical functionalities are destroyed, and rearrangements of alkyl moieties within or between functional groups or substituents, or divisions or combinations of alkyl moieties, that do not create new chemical functionalities or destroy existing chemical functionalities, would be within the definition of positional isomer.
    IV. "Synthetic drug'' means any substance within the following structural classes:
       (a) Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with a substituent at the 5-position of the phenolic ring: whether or not substituted on the cyclohexyl ring to any extent.
       (b) Any compound containing a 1-(1-naphthylmethyl)indene ring system with a substituent at the 3-position of the indene ring system: whether or not further substituted on the indene ring to any extent, and whether or not substituted on the naphthyl ring to any extent.
       (c) Any compound containing an indole ring system with a substituent on the nitrogen atom and bearing an additional substituent at the 3-position of the indole ring system, with a linkage connecting the ring system to the substituent:
          (1) Where the linkage connecting the indole ring system to the substituent at its 3-position is any of the following:
             (A) Alkyl.
             (B) Carbonyl.
             (C) Ester.
             (D) Thione.
             (E) Thioester.
             (F) Amino.
             (G) Alkylamino.
             (H) Amido.
             (I) Alkylamido.
          (2) Where the substituent at the 3-position of the indole ring system is, disregarding the linkage, any of the following groups:
             (A) Naphthyl.
             (B) Quinolinyl.
             (C) Adamantyl.
             (D) Phenyl.
             (E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).
             (F) Biphenyl.
             (G) Allcylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).
             (H) Benzyl.
             (I) Carboxylic acid.
             (J) Ester.
             (K) Ether.
             (L) Phenylpropylamido.
             (M) Phenylopropylamino.
          (3) Whether or not the substituent at the 3-position of the indole ring system, disregarding the linkage, is further substituted to any extent.
          (4) Whether or not further substituted on the indole ring system to any extent.
       (d) Any compound containing an indazole ring system with a substituent at the 1-position nitrogen atom and bearing an additional substituent at the 3-position of the indazole ring system, with a linkage connecting the ring system to the substituent:
          (1) Where the linkage connecting the indazole ring system to the substituent at its 3-position is any of the following:
             (A) Alkyl.
             (B) Carbonyl.
             (C) Ester.
             (D) Thione.
             (E) Thioester.
             (F) Amino.
             (G) Alkylamino.
             (H) Amido.
             (I) Alkylamido.
          (2) Where the substituent at the 3-position of the indazole ring system is, disregarding the linkage, any of the following groups:
             (A) Naphthyl.
             (B) Quinolinyl.
             (C) Adamantyl.
             (D) Phenyl.
             (E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).
             (F) Biphenyl.
             (G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).
             (H) Benzyl.
             (I) Carboxylic acid.
             (J) Ester.
             (K) Ether.
             (L) Phenylpropylamido.
             (M) Phenylopropylamino.
          (3) Whether or not the substituent at the 3-position of the indazole ring system, disregarding the linkage, is further substituted to any extent.
          (4) Whether or not further substituted on the indazole ring system to any extent.
       (e) Any compound containing a pyrrole ring with a substituent on the nitrogen atom and bearing an additional substituent at the 3-position of the pyrrole ring, with a linkage connecting the ring to the substituent:
          (1) Where the linkage connecting the pyrrole ring to the substituent at its 3-position is any of the following:
             (A) Alkyl.
             (B) Carbonyl.
             (C) Ester.
             (D) Thione.
             (E) Thioester.
             (F) Amino.
             (G) Alkylamino.
             (H) Amido.
             (I) Alkylamido.
          (2) Where the substituent at the 3-position of the pyrrole ring is, disregarding the linkage, any of the following groups:
             (A) Naphthyl.
             (B) Quinolinyl.
             (C) Adamantyl.
             (D) Phenyl.
             (E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).
             (F) Biphenyl.
             (G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).
             (H) Benzyl.
             (I) Carboxylic acid.
             (J) Ester.
             (K) Ether.
             (L) Phenylpropylamido.
             (M) Phenylopropylamino.
          (3) Whether or not the substituent at the 3-position of the pyrrole ring, disregarding the linkage, is further substituted to any extent.
          (4) Whether or not further substituted on the pyrrole ring to any extent.
       (f) Any compound containing a pyrazole ring with a substituent at the 1-position nitrogen atom and bearing an additional substituent at the 3-position of the pyrazole ring with a linkage connecting the ring to the substituent:
          (1) Where the linkage connecting the pyrazole ring to the substituent at its 3-position is any of the following:
             (A) Alkyl.
             (B) Carbonyl.
             (C) Ester.
             (D) Thione.
             (E) Thioester.
             (F) Amino.
             (G) Alkylamino.
             (H) Amido.
             (I) Alkylamido.
          (2) Where the substituent at the 3-position of the pyrazole ring is, disregarding the linkage, any of the following groups:
             (A) Naphthyl.
             (B) Quinolinyl.
             (C) Adamantyl.
             (D) Phenyl.
             (E) Cyclopentyl, or cyclohexyl.
             (F) Cycloalkyl (limited to cyclopropyl, cyclobutyl, or biphenyl).
             (G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).
             (H) Benzyl.
             (I) Carboxylic acid.
             (J) Ester.
             (K) Ether.
             (L) Phenylpropylamido.
             (M) Phenylopropylamino.
          (3) Whether or not the substituent at the 3-position of the pyrazole ring, disregarding the linkage, is further substituted to any extent.
          (4) Whether or not further substituted on the pyrazole ring to any extent.
       (g) Any compound containing a pyrazole ring with a substituent at the 1-position nitrogen atom and bearing an additional substituent at the 3-position of the pyrazole ring with a linkage connecting the ring to the substituent:
          (1) Where the linkage connecting the pyrazole ring to the substituent at its 3 position is any of the following:
             (A) Alkyl.
             (B) Carbonyl.
             (C) Ester.
             (D) Thione.
             (E) Thioester.
             (F) Amino.
             (G) Alkylamino.
             (H) Amido.
             (I) Alkylamido.
          (2) Where the substituent at the 3 position of the pyrazole ring is, disregarding the linkage, any of the following groups:
             (A) Naphthyl.
             (B) Quinolinyl.
             (C) Adamantyl.
             (D) Phenyl.
             (E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).
             (F) Biphenyl.
             (G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).
             (H) Benzyl.
             (I) Carboxylic acid.
             (J) Ester.
             (K) Ether.
             (L) Phenylpropylamido.
             (M) Phenylpropylamino.
          (3) Whether or not the substituent at the 3 position of the pyrazole ring, disregarding the linkage, is further substituted to any extent.
          (4) Whether or not further substituted on the pyrazole ring to any extent.
       (h) Any compound containing a naphthalene ring system with a substituent on the 1 position carbon atom and bearing an additional substituent at the 4 position of the naphthalene ring system, with a linkage connecting the ring system to the substituent:
          (1) Where the linkage connecting the naphthalene ring system to the substituent at its 4 position is any of the following:
             (A) Alkyl.
             (B) Carbonyl.
             (C) Ester.
             (D) Thione.
             (E) Thioester.
             (F) Amino.
             (G) Alkylamino.
             (H) Amido.
             (I) Alkylamido.
          (2) Where the substituent at the 4 position of the naphthalene ring system is, disregarding the linkage, any of the following groups:
             (A) Naphthyl.
             (B) Quinolinyl.
             (C) Adamantyl.
             (D) Phenyl.
             (E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).
             (F) Biphenyl.
             (G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).
             (H) Benzyl.
             (I) Carboxylic acid.
             (J) Ester.
             (K) Ether.
             (L) Phenylpropylamido.
             (M) Phenylpropylamino.
          (3) Whether or not the substituent at the 4 position of the naphthalene ring system, disregarding the linkage, is further substituted to any extent.
          (4) Whether or not further substituted on the naphthalene ring system to any extent.
       (i) Any compound containing a carbazole ring system with a substituent on the nitrogen atom and bearing an additional substituent at the 1, 2, or 3 position of the carbazole ring system, with a linkage connecting the ring system to the substituent:
          (1) Where the linkage connecting the carbazole ring system to the substituent at its 1, 2, or 3 position is any of the following:
             (A) Alkyl.
             (B) Carbonyl.
             (C) Ester.
             (D) Thione.
             (E) Thioester.
             (F) Amino.
             (G) Alkylamino.
             (H) Amido.
             (I) Alkylamido.
          (2) Where the substituent at the 1, 2, or 3 position of the carbazole ring system is, disregarding the linkage, any of the following groups:
             (A) Naphthyl.
             (B) Quinolinyl.
             (C) Adamantyl.
             (D) Phenyl.
             (E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).
             (F) Biphenyl.
             (G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).
             (H) Benzyl.
             (I) Carboxylic acid.
             (J) Ester.
             (K) Ether.
             (L) Phenylpropylamido.
             (M) Phenylpropylamino.
          (3) Whether or not the substituent at the 1, 2, or 3 position of the carbazole ring system, disregarding the linkage, is further substituted to any extent.
          (4) Whether or not further substituted on the carbazole ring system to any extent.
       (j) Any substance which includes, but is not limited to the following:
          (1) QUCHIC/BB-22.
          (2) STS-135.
          (3) APICA/SDB-001.
          (4) ADBICA.
          (5) ADB-FUBINACA.
          (6) AB-001.
          (7) SDB-006.
          (8) EG-018.
          (9) CB-13.
          (10) 5-chloro-UR-144.
          (11) FUB-PB-22.
       (k) Any synthetic cathinone, which shall be defined as any of the following chemical structures, their salts, isomers and salts of isomers, whenever the existence of these is possible within the specific chemical designation, including any compound structurally derived from 2-aminopropanal by substitution at the 1-position with a monocyclic or fused polycyclic ring system, including compounds further modified by:
          (1) Substitution on the ring system to any extent (including, but not limited to alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents), whether or not further substituted in the ring system by other substituents; and/or
          (2) Substitution at the 3-position with a saturated or unsaturated hydrocarbon substituent; and/or
          (3) Mono- or di- substitution at the 2-amino nitrogen atom with saturated or unsaturated hydrocarbon groups, or inclusion of the 2-amino nitrogen atom in a cyclic structure, whether or not that cyclic structure contains any further substitutions;
          (4) Includes, but is not limited to:
             (A) 3,4-dimethylmethcathinone (3,4-DMMC)
             (B) Beta-keto-ethylbenzodioxolylbutanamine (eutylone)
             (C) 3,4-methylenedioxy-N-ethylcathinone (ethylone)
          (5) 4-methoxymethcathinone (methedrone). This term shall not include substances that are otherwise scheduled under the Controlled Substances Act: (e.g. cathinone, methcathinone, methylone, mephedrone, MDPV, diethylpropion, pyrovalerone), are FDA-approved pharmaceutical products (i.e. bupropion), or are FDA-approved research products.
       (l) Any synthetic psychoactive compound or substance which shall be defined as substances and their salts, isomers, and salts of isomers, wherever the existence of these is possible, within the following specific chemical designation:
          (1) 2,5-dimethoxy-4-methyl-N-(2-methoxybenzyl)phenethylamine (also known as 25D-NBOMe).
          (2) 2,5-dimethoxy-4-ethyl-N-(2-methoxybenzyl)phenethylamine (also known as 25E-NBOMe).
          (3) 2,5-dimethoxy-4-nitro-N-(2-methoxybenzyl)phenethylamine (also known as 25N-NBOMe).
          (4) 2,5-dimethoxy-4-n-propyl-N-(2-methoxybenzyl)phenethylamine (also known as 25P-NBOMe).
          (5) 2,5-dimethoxy-4-ethylthio-N-(2-methoxybenzyl)phenethylamine (also known as 25T2-NBOMe).
          (6) 2,5-dimethoxy-4-sec-propylthio-N-(2-methoxybenzyl)phenethylamine (also known as 25T4-NBOMe).
          (7) 2,5-dimethoxy-4-n-propylthio-N-(2-methoxybenzyl)phenethylamine (also known as 25T7-NBOMe).
          (8) N-(2-methoxybenzyl)-3,4-dimethoxyamphetamine (also known as 34-DMA NBOMe).
          (9) 1-(1-Benzofuran-2-yl)propan-2-amine (also known as 2-APB).
          (10) 5-(2-aminopropyl)-2,3-dihydrobenzofuran (also known as 5-APDB).
          (11) 2-(2-ethylaminopropyl)benzofuran (also known as 2-EAPB).
          (12) 1-(Benzofuran-5-yl)-N-methylpropan-2-amine (also known as 5-MAPB).
          (13) 3,4-dichloromethylphenidate.
          (14) 5,6-methylenedioxy-2-aminoindan (also known as 5,6-MDAI).
          (15) 4-hydroxy-diethyltryptamine (also known as 4-hydroxy-DET).
          (16) 4-methoxyphencyclidine (also known as 4-methoxy-PCP or methoxydine).
          (17) 3,4-dichloro-N-([1-(dimethylamino)cyclohexyl]methyl)benzamide (also known as AH-7921).
          (18) Benocyclidine (also known as BTCP).
          (19) Methoxetamine (also known as MXE).
          (20) 3-Methyl-6-[3-trifluoromethyl)phenyl]-1,2,4-triazolo[4,3-b]pyridazine (also known as CL218872).
          (21) 1-(1,2-diphenylethyl)piperidine (also known as diphenidine).
          (22) 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (also known as MT-45).
          (23) (3-diethylamino-2,2-dimethylpropyl)-4-nitrobenzoate (also known as nitrocaine or nitracaine).
          (24) (E)-4-chloro-N-1(phenylethylpiperidin-2-ylidene)sulfonamide (also known as W-15).
          (25) (E)-4-chloro-N-(1-(4-nitrophenylethyl)piperidin-2-ylidene)sulfonamide (also known as W-18).
          (26) 4-fluoroamphetamine.
          (27) 1-(thiophen-2-yl)-2-methylaminopropane (also known as methiopropamine).
       (m) This definition shall not include:
          (1) Endocannabinoids that are naturally found in the human body;
          (2) Delta-9 Tetrahydrocannabinol (THC) or other marijuana-derived cannabinoids, in the form of marinol, dronabinol, or another generic pharmaceutical equivalent, provided the medication has been issued as the result of a valid prescription; or
          (3) Any other drugs that have cannabinoid receptor activity that are currently approved by the United States Food and Drug Administration for medical use; or marijuana and extracts of marijuana authorized for therapeutic use pursuant to RSA 126-X.

Source. 2015, 204:6, eff. July 6, 2015.